What is the best way to measure response to GvHD treatment?

L: English

During the 61st American Society of Hematology (ASH) meeting, Orlando, US, the GvHD Hub were pleased to host a discussion between James Ferrara and Hrishikesh Srinagesh, both from the Icahn School of Medicine at Mount Sinai, New York, US, on what is the best way to measure response to GvHD treatment? Hrishikesh Srinagesh talks about two recently validated biomarkers to measure GvHD severity. He also discusses his study that explored if the Mount Sinai Acute GvHD International Consortium (MAGIC) algorithm probability (MAP) could successfully predict long-term outcomes.

Was this article informative? Thank you for your feedback!